| Name | Gatifloxacin hydrochloride |
| Description | Gatifloxacin hydrochloride (AM-1155 hydrochloride) is a fourth-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. |
| Animal Research | Heptanol-induced corneal ulcers in New Zealand White rabbits (n = 41; 8 females/group) were inoculated with 10(6) CFU of Pseudomonas aeruginosa. Gatifloxacin 0.3% dosing varied among 4 groups with frequencies of 16-48 doses/day (days 1-2), 3-16 doses/day (days 3-7), and maintenance dosing of 3-4 doses/day (days 8-22). Ciprofloxacin 0.3% was administered as labeled for corneal ulcers, with 44 doses on day 1, 16 doses on day 2, and 4 doses/day on days 3-21[1] |
| In vivo | All eyes showed evidence of infection by 48 hours postinoculation with 36 of 41 eyes (87.8%) exhibiting moderate-to-severe keratitis. All eyes exhibited corneal healing by day 15, with no significant differences among groups. Three of 4 groups receiving gatifloxacin tended to have smaller fluorescein retention area scores than did the ciprofloxacin group. No eyes tested positive for Pseudomonas at the end of the study. No corneal precipitates were found following as many as 48 doses/day of gatifloxacin[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 10 mg/mL (24.28 mM), Sonication is recommended.
DMSO : 4.12 mg/mL (10 mM), Sonication is recommended.
|
| Keywords | Topoisomerase | S. aureus | PD-135432 | PD135432 | PD 135432 | N. brasiliensis | Inhibitor | inhibit | hypoglycemia | hyperglycemia | Gatifloxacin hydrochloride | Gatifloxacin | E. coli,?Pseudomonas aeruginosa,?Micrococcus luteus | diabetic | conjunctivitis | BMS-206584 | BMS206584 | BMS 206584 | Bacterial | Antibiotic | AM-1155 | AM1155 | AM 1155 | actinomycetoma |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Bioactive Compound Library | Approved Drug Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | NMPA-Approved Drug Library |
United States
